European Microbiome Congress | Kisaco Research
London, UK
27-29 November, 2017
Download Agenda
Speakers
Register

Why Attend

The Annual European Microbiome Congress has become a trusted learning and networking platform for leading academics, practicing clinicians, pharmaceutical and nutrition companies, biotech entrepreneurs and investors, government and regulatory bodies and industry leaders who require insight into the latest microbiome research, clinical trials and multi-disciplinary collaborations.

Join us for 2.5 days of intense networking, unpublished research and translational case studies.

In addition to the open networking available, our ‘MEETING MOJO’ platform allows you to create a bespoke meeting schedule, promoting productive collaboration; and if you are looking to highlight your recent work to the wider microbiome community, the dedicated poster session is a great way to get your research noticed and further involve yourself with the congress!

Our 2017 agenda is now available to view here.

200+
Delegates
50:50
Ratio of Academics - Industry
5+
Microbiome Niches Covered
40+
Leading Top Speakers
10
Hours of Dedicated Networking

View Video from European Microbiome Congress 2016

European Microbiome Congress, 2016

Who Will Be There

The Speakers

 

Esther Jiménez

Project Manager
Probisearch

Esther Jiménez

Project Manager
Probisearch
 

Jean de Gunzburg

CSO
Davoltera

Talk to me about… your research

Jean de Gunzburg

CSO
Davoltera

Talk to me about… your research

I am the chief scientific officer at Da Volterra, a French biotechnology company, headquartered in Paris, France. Da Volterra is committed to the discovery and development of innovative approaches to prevent the deleterious consequences of antibiotic treatments on the intestinal microbiota, including the emer­gence and dissemination of antimicrobial resistance, as well as the occurrence of infections by opportunistic pathogens such as Clostridium difficile. Prior to that, I led an academic career as a cell biologist focusing on signal transduction and oncogenesis, ultimately leading a research laboratory at the Institut Curie in Paris.

 

Talk to me about…something people may not know about you

I was born in Canada, lived for most of my life in France, and am now based in the London. I am an avid off-piste skier, in the French and Swiss Alps. I particularly enjoy the slow hiking/skinning up the mountains which gives me time to appreciate the fabulous scenery, and to think in depth about new and arising matters, in particular in relation to my research.

 

Sacha Mann

CEO
Biosys UK

Sacha Mann

CEO
Biosys UK
 

Lihi Segal

CEO
Day Two

Lihi Segal

CEO
Day Two
 

Muriel Derrien

Gut Microbiota Program Leader
Danone Nutricia Research

Muriel Derrien

Gut Microbiota Program Leader
Danone Nutricia Research
 

Prof. Dr. Michael Schloter

Head of the Research Unit for Comparative Microbiome Analyses
Helmholtz Zentrum München

Prof. Dr. Michael Schloter

Head of the Research Unit for Comparative Microbiome Analyses
Helmholtz Zentrum München
 

Professor Curtis Huttenhower

Associate Professor of Computational Biology and Bioinformatics
Harvard School of Public Health

Talk to me about… your research

Professor Curtis Huttenhower

Associate Professor of Computational Biology and Bioinformatics
Harvard School of Public Health

Talk to me about… your research

I am a Professor in Biostatistics at the Harvard T.H. Chan School of Public Health and an Associate Member at the Broad Institute.  I participated extensively in the NIH Human Microbiome Project and co-leads the "HMP2" Center for Characterizing the gut microbial ecosystem in IBD and the Human Microbiome Bioactives Resource.  My  lab focuses on computational methods for functional analysis of microbial communities.  This includes systems biology reconstructions integrating metagenomic, metatranscriptomic, and other microbial community 'omics, the human microbiome in autoimmune disease such as IBD, and its potential as a biomarker and route for therapeutic intervention.

 

Talk to me about…something people may not know about you

I'm a happy kitty parent, most recently of two new kittens who (like human babies) have as yet to learn to sleep through the night. I wish I had as much energy as they do!

 

Amrita Ahluwalia

Prof of Vascular Pharmacology
Queen Mary University of London

Amrita Ahluwalia

Prof of Vascular Pharmacology
Queen Mary University of London
 

Andrew Morgan

DuPont Fellow & Chief Scientist
Dupont Nutrition & Health

Andrew Morgan

DuPont Fellow & Chief Scientist
Dupont Nutrition & Health
 

Arpita Maiti

Senior Director, External R&D Innovation, Inflammation & Immunology and Microbiome
University of Oxford

Arpita Maiti

Senior Director, External R&D Innovation, Inflammation & Immunology and Microbiome
University of Oxford
 

Marie Drago

Founder
Gallinee

Marie Drago is a French Doctor in Pharmacy and a member of the French Society of Cosmetic Science, with over 15 years’ experience working for successful and innovative skincare brands. After discovering how a prebiotic and probiotic diet could improve the symptoms of the gluten intolerance that had been plaguing her life for years, Marie got a Eureka moment: What if we applied the same science to skin?

Marie Drago

Founder
Gallinee

Marie Drago is a French Doctor in Pharmacy and a member of the French Society of Cosmetic Science, with over 15 years’ experience working for successful and innovative skincare brands. After discovering how a prebiotic and probiotic diet could improve the symptoms of the gluten intolerance that had been plaguing her life for years, Marie got a Eureka moment: What if we applied the same science to skin?

Marie’s thesis on the microbiome and the enormous benefits of harnessing helpful bacteria gave her the vision and the know-how to create Gallinée’s formulations. Thanks to her pharmacy background and her beauty experience, Marie designed formulas like no other, and patented the triple biotic complex that you can now find in Gallinée’s products.

 

 

Dr. Larry Weiss

CEO & Founder
Persona Biome

Talk to me about… your business

Dr. Larry Weiss

CEO & Founder
Persona Biome

Talk to me about… your business

I am the CEO and Founder of Persona Biome, a San Francisco skin microbiome company.  Previously, I was Chief Medical Officer at AOBiome where I formulated and developed the Mother Dirt cosmetics, including AO Mist, the first live skin probiotic. I have an extensive background in natural products chemistry, microbiology, clinical medicine, dermatology, and pharmaceutical and cosmetic product development. I am board certified in Anesthesiology, have an MD from Stanford University, and a BS in Biochemistry from Cornell University. I have multiple patents and publications in the areas of chemistry, electrophysiology, clinical pharmacology, and the microbiome. I am a Co-Founder of CleanWell Company.

 

 

 

Dr David Cook

Chief Scientific Officer
Seres

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. (“Seres”). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr.

Dr David Cook

Chief Scientific Officer
Seres

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. (“Seres”). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.

 

Céline Druart

Assistant Researcher, Metabolism and Nutrition Research Group
Louvain Drug Research Institute

Céline Druart

Assistant Researcher, Metabolism and Nutrition Research Group
Louvain Drug Research Institute
 

Dr James Kinross

Senior Lecturer in Colorectal Surgery
Imperial College London

Dr. James Kinross is a consultant colorectal surgeon, at St. Mary’s Hospital London. His clinical interests are in minimally invasive and laparoscopic surgery for the treatment of colorectal cancer. He also has an interest in surgical nutrition and modulation of the gut microbiota by pro and prebiotics for improved operative outcomes. He was trained in Northwest London, and he was an NIHR Clinical Lecturer in Surgery and an Ethicon Laparoscopic Fellow in Colorectal Surgery.

Dr James Kinross

Senior Lecturer in Colorectal Surgery
Imperial College London

Dr. James Kinross is a consultant colorectal surgeon, at St. Mary’s Hospital London. His clinical interests are in minimally invasive and laparoscopic surgery for the treatment of colorectal cancer. He also has an interest in surgical nutrition and modulation of the gut microbiota by pro and prebiotics for improved operative outcomes. He was trained in Northwest London, and he was an NIHR Clinical Lecturer in Surgery and an Ethicon Laparoscopic Fellow in Colorectal Surgery. He was awarded a Royal College of Surgeons of England training fellowship during his PhD and he was funded by the Academy of Medical Sciences as an early stage lecturer. He is a visiting Professor at the Royal College of Surgeons of Ireland. He is currently funded by Bowel and Cancer research and the Imperial BRC.

 

Shannon Doyle

Founder
SmartFLora

Shannon Doyle

Founder
SmartFLora
 

Johan van Hylckama Vlieg

Vice President Microbiome & Human Health Innovation
Chr. Hansen A/S

Johan E.T. van Hylckama Vlieg is currently Senior Director Microbiome at Chr. Hansen AS, one of the largest microbe producing companies in the world. He is responsible for microbiome innovation program and heading the microbiome research and pilot facility. He has 20 years of experience and leadership in gut microbiology, probiotics and food biotechnology in industry and academia. He is (co)author of more than 70 peer-reviewed publications and inventor of 13 patents or patent applications.

Johan van Hylckama Vlieg

Vice President Microbiome & Human Health Innovation
Chr. Hansen A/S

Johan E.T. van Hylckama Vlieg is currently Senior Director Microbiome at Chr. Hansen AS, one of the largest microbe producing companies in the world. He is responsible for microbiome innovation program and heading the microbiome research and pilot facility. He has 20 years of experience and leadership in gut microbiology, probiotics and food biotechnology in industry and academia. He is (co)author of more than 70 peer-reviewed publications and inventor of 13 patents or patent applications.

 

Professor Julian Marchesi

Professor of Human Microbiome Research
Cardiff University

Julian Marchesi graduated from Cardiff University with a PhD in biochemistry (1992) and became interested in the role bacteria play in ecosystem function. During his post-doctoral years he developed an interest in the contribution of uncultured microbes to the maintenance and function of ecosystems i.e. molecular microbial ecology.

Professor Julian Marchesi

Professor of Human Microbiome Research
Cardiff University

Julian Marchesi graduated from Cardiff University with a PhD in biochemistry (1992) and became interested in the role bacteria play in ecosystem function. During his post-doctoral years he developed an interest in the contribution of uncultured microbes to the maintenance and function of ecosystems i.e. molecular microbial ecology. He subsequently secured a Wellcome Trust Fellowship which extended his molecular microbial ecology interest and investigated, with culture independent methods, the diversity and distribution of genes involved in biodegradation of priority pollutants in pristine environments. After a short time investigating the deep biosphere he obtained a Lectureship (2001) in the Department of Microbiology, University College Cork, Ireland where he transferred these “omic” skills into the human gut and started to investigate the human gut ecosystem in health and disease. After 7 years in UCC, he moved back to Cardiff University in 2008 to a senior lectureship, where he investigates the role of the gut microbiome in maintaining host health and initiating diseases not only of the gut, but throughout the host system. In 2013 he was promoted to Reader and also took a half time Readership in Digestive Health at Imperial College London.

 

David Kyle

Chairman of the Board, Chief Scientific Officer
Evolve Biosystems

Talk to me about… your research 

I am the Chairman and CSO of Evolve Biosystems Inc and a 30-year veteran of biotech having co-founded a range of successful biotech companies in the fields of nutrition and health. These include Martek Biosciences that focuses on DHA and ARA nutrition for infants, which was acquired by DSM in 2011 for $1.1 Billion and Evolve BioSystems the leader in the field of the infant microbiome. I am trained as a biochemist and have spent most of my career working with mothers and babies, focusing specifically on infant nutrition.

David Kyle

Chairman of the Board, Chief Scientific Officer
Evolve Biosystems

Talk to me about… your research 

I am the Chairman and CSO of Evolve Biosystems Inc and a 30-year veteran of biotech having co-founded a range of successful biotech companies in the fields of nutrition and health. These include Martek Biosciences that focuses on DHA and ARA nutrition for infants, which was acquired by DSM in 2011 for $1.1 Billion and Evolve BioSystems the leader in the field of the infant microbiome. I am trained as a biochemist and have spent most of my career working with mothers and babies, focusing specifically on infant nutrition.

Talk to me about…something people may not know about you

 I am the named inventor on over 250 patents and was inducted into the US Technology Hall of Fame in 200 for my contributions to Science and Industry. I am passionately engaged in bringing new technologies into commerce to improve the life-long health trajectory of all infants worldwide

 

Professor David Berry

Associate Professor, Microbial Ecology
University of Vienna

David Berry is Associate Professor at the University of Vienna.

His research interests include:

  • Function of the intestinal microbiota in health and disease
  • Numerical approaches to study microbial communities
  • Development of molecular and isotope-labeling methods for studying uncultivated microorganisms in their natural environment

He has 28 publications in peer-reviewed journals, including in leading multidisciplinary and discipline-specific journals such as: Proc Natl Acad Sci USA, Cancer Res, FEMS Microbiol Rev, and ISME J.

Professor David Berry

Associate Professor, Microbial Ecology
University of Vienna

David Berry is Associate Professor at the University of Vienna.

His research interests include:

  • Function of the intestinal microbiota in health and disease
  • Numerical approaches to study microbial communities
  • Development of molecular and isotope-labeling methods for studying uncultivated microorganisms in their natural environment

He has 28 publications in peer-reviewed journals, including in leading multidisciplinary and discipline-specific journals such as: Proc Natl Acad Sci USA, Cancer Res, FEMS Microbiol Rev, and ISME J.

 

Dr Trevor Lawley

CSO
Microbiotica

Trevor obtained his PhD from the University of Alberta, Canada, where he studied the mechanisms that pathogenic bacteria use to disseminate antibiotic resistance genes. In 2010, Trevor was appointed as a Career Development Fellow in the Sanger Institute Faculty and was promoted to Group Leader in 2014. He receives funding from the Medical Research Council. Trevor’s research investigates the mechanisms that underlie how micro-organisms on mucosal surfaces (gut, nasopharnyx, uro-gential tract) interact with their host during periods of health and disease.

Dr Trevor Lawley

CSO
Microbiotica

Trevor obtained his PhD from the University of Alberta, Canada, where he studied the mechanisms that pathogenic bacteria use to disseminate antibiotic resistance genes. In 2010, Trevor was appointed as a Career Development Fellow in the Sanger Institute Faculty and was promoted to Group Leader in 2014. He receives funding from the Medical Research Council. Trevor’s research investigates the mechanisms that underlie how micro-organisms on mucosal surfaces (gut, nasopharnyx, uro-gential tract) interact with their host during periods of health and disease. In particular, he seeks to develop novel ways to treat diseases that are associated with unwanted imbalances in the micro-organism communities.

 

Professor Tim Spector

Professor of Genetic Epidemiology
Kings College London

Tim Spector is a Professor of Genetic Epidemiology and Director of the TwinsUK Registry at Kings College, London. He trained originally in rheumatology and epidemiology. In 1992 he moved into genetic epidemiology and founded the UK Twins Registry, of 13,000 twins, which is the richest collection of genotypic and phenotypic information worldwide. He is past President of the International Society of Twin Studies, directs the European Twin Registry Consortium (Discotwin) and collaborates with over 120 centres worldwide.

Professor Tim Spector

Professor of Genetic Epidemiology
Kings College London

Tim Spector is a Professor of Genetic Epidemiology and Director of the TwinsUK Registry at Kings College, London. He trained originally in rheumatology and epidemiology. In 1992 he moved into genetic epidemiology and founded the UK Twins Registry, of 13,000 twins, which is the richest collection of genotypic and phenotypic information worldwide. He is past President of the International Society of Twin Studies, directs the European Twin Registry Consortium (Discotwin) and collaborates with over 120 centres worldwide. He has demonstrated the genetic basis of a wide range of common complex traits, many previously thought to be mainly due to ageing and environment. Through genetic association studies (GWAS), his group have found over 500 novel gene loci in over 50 disease areas. He has published over 800 research articles and is ranked as being in the top 1% of the world’s most cited scientists by Thomson-Reuters as well as the most cited scientist at King’s College London. He held a prestigious European Research Council senior investigator award in epigenetics and is a NIHR Senior Investigator and is a Fellow of the UK Academy of Medical Sciences. His current work focuses on omics and the microbiome and directs the crowdfunded British Gut microbiome project. He is a prolific writer with several popular science books and a regular blog, focusing on genetics, epigenetics and most recently microbiome and diet (The Diet Myth). He is in demand as a public speaker and features regularly in the media.

 

Professor Max Nieuwdorp

Professor of internal medicine and diabetes
AMC Amsterdam

Dr Nieuwdorp is currently working as an internist-endocrinologist and Head of the department of Experimental Vascular Medicine at the Academic Medical Centre (AMC) within the University of Amsterdam. He has initiated a translational research group focused on dissecting the causal role of (small) intestinal bacterial strains to reverse insulin resistance, adipose tissue inflammation and cardiovascular disease. Dr Niuewdorp is also Visiting Professor at the University of Gothenburg.

Professor Max Nieuwdorp

Professor of internal medicine and diabetes
AMC Amsterdam

Dr Nieuwdorp is currently working as an internist-endocrinologist and Head of the department of Experimental Vascular Medicine at the Academic Medical Centre (AMC) within the University of Amsterdam. He has initiated a translational research group focused on dissecting the causal role of (small) intestinal bacterial strains to reverse insulin resistance, adipose tissue inflammation and cardiovascular disease. Dr Niuewdorp is also Visiting Professor at the University of Gothenburg. He has previously completed a residency in internal medicine and a fellowship at AMC Amsterdam and a postdoctoral fellowship in glycobiology at University College San Diego, USA.

 

Joseph Sliman

Chief Medical Officer (CMO)
Synthetic Biologics

From January 13, 2014 until January 17, 2017, Dr. Sliman served as the Company’s Senior Vice President-Clinical & Regulatory Affairs. Dr. Sliman has more than 18 years of experience in clinical and public health research, including 10 years directing clinical projects and product development, in therapeutic areas such as infectious diseases and vaccines. From September 2012 until January 2014, Dr.

Joseph Sliman

Chief Medical Officer (CMO)
Synthetic Biologics

From January 13, 2014 until January 17, 2017, Dr. Sliman served as the Company’s Senior Vice President-Clinical & Regulatory Affairs. Dr. Sliman has more than 18 years of experience in clinical and public health research, including 10 years directing clinical projects and product development, in therapeutic areas such as infectious diseases and vaccines. From September 2012 until January 2014, Dr. Sliman served as Senior Medical Director and Head of Patient Safety and Pharmacovigilance at Vanda Pharmaceuticals Inc., where he directed efforts for a New Drug Application for HETLIOZ (tasimelteon), which is indicated for the treatment of Non-24 Hour Disorder in totally blind adults. From December 2008 until August 2012, Dr. Sliman served as Medical Director in Vaccines and Infectious Diseases at MedImmune, Inc., where he was a member of successful Biologics Licensure Application teams. Prior to joining MedImmune, Inc., he served as Associate Medical Director at Dynport Vaccine Company, where he was the clinical director for seasonal and pandemic influenza vaccine trials as well as its Defense Vaccines development program (partnered with Department of Defense Joint Vaccines Acquisition Program).  During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University, a Master’s Degree in Public Health from the Johns Hopkins University School of Public Health, and a B.S. in Molecular and Cell Biology, with Honors in Biology, from Pennsylvania State University.

 

Professor Jeroen Raes

Group Leader Bioinformatics and (eco-)Systems Biology
VIB, KULeuven

Jeroen Raes is group leader of the Bioinformatics and (eco-)Systems Biology (BSB) research group at VIB in Brussels. He has an extensive track record in meta-omics and microbiome research.

Professor Jeroen Raes

Group Leader Bioinformatics and (eco-)Systems Biology
VIB, KULeuven

Jeroen Raes is group leader of the Bioinformatics and (eco-)Systems Biology (BSB) research group at VIB in Brussels. He has an extensive track record in meta-omics and microbiome research. He is associate editor for ISME journal, Scientific Reports (Nature publishing group), SIGS and Genomics Insights and is reviewer and/or committee member for ANR/NWO/FWO/ERC proposals.The Raes lab combines large-scale, next-generation sequencing with novel computational approaches to investigate the functioning and variability of the healthy human microbiome at the systems level and studies its alteration in disease.

 

Dr. Gregor Reid

Professor of Microbiology and Immunology and Surgery
Western University

Dr. Gregor Reid is a professor of Microbiology and Immunology and Surgery at Western University, and the Endowed Chair in Human Microbiome and Probiotics at the Lawson Health Research Institute. Dr. Reid’s research interests include: Microbiome and probiotics, Women’s health, Environmental influences on health, and Genitourinary systems. Having been a pioneer of probiotic research and the study of microbes in the urogenital tract of women, his research has expanded to studies of the gut, breast, heart and use of probiotics to detoxify environmental pollutants. Dr.

Dr. Gregor Reid

Professor of Microbiology and Immunology and Surgery
Western University

Dr. Gregor Reid is a professor of Microbiology and Immunology and Surgery at Western University, and the Endowed Chair in Human Microbiome and Probiotics at the Lawson Health Research Institute. Dr. Reid’s research interests include: Microbiome and probiotics, Women’s health, Environmental influences on health, and Genitourinary systems. Having been a pioneer of probiotic research and the study of microbes in the urogenital tract of women, his research has expanded to studies of the gut, breast, heart and use of probiotics to detoxify environmental pollutants. Dr. Gregor Reid’s research primarily focuses on beneficial microbes, and he is one of the world’s foremost experts on probiotics, (microorganisms that produce many health benefits). To date, he has developed novel probiotic therapies used by several million people around the world. He has also held 28 patents, published over 500 peer-reviewed publications, in highly prestigious academic journals including Lancet, JAMA, PNAS, PLoS One, Nature and Nature Reviews Microbiology; he has also given >600 talks in 54 countries, and has a Google Scholar H factor of 81.

 

Denise Kelly

Investment Advisor
Seventure

Denise joined Seventure in September 2015 as an investment Advisor to the Life Sciences Team for microbiome field.

Her focus is in Human Microbiome Research and her time is dedicated to coverage of scientific and academic community on behalf of Seventure, and to prospect new investment opportunities in the specific field of microbiome.

Denise Kelly

Investment Advisor
Seventure

Denise joined Seventure in September 2015 as an investment Advisor to the Life Sciences Team for microbiome field.

Her focus is in Human Microbiome Research and her time is dedicated to coverage of scientific and academic community on behalf of Seventure, and to prospect new investment opportunities in the specific field of microbiome.

Denise is currently based in Aberdeen, Scotland. Prior to joining Seventure, Denise was Head of her Research team at the World-renowned Rowett Institute, University of Aberdeen, where she acquired over 20 years experience in gut microbiology and immunology. She was the (former) Founder Director, CEO and CSO of GT Biologics Ltd, one of the first translational spinouts, developing Innovative Microbiome-based Therapies.

 

Ian MacLeod

Senior Associate
Carpmaels & Ransford

Ian is a UK and European Patent Attorney and his practice covers a wide range of biotechnological subject-matter, with particular focus on live biotherapeutics, biomarker diagnostics, vaccines, antibody therapeutics, and antisense nucleotides.

 

Ian MacLeod

Senior Associate
Carpmaels & Ransford

Ian is a UK and European Patent Attorney and his practice covers a wide range of biotechnological subject-matter, with particular focus on live biotherapeutics, biomarker diagnostics, vaccines, antibody therapeutics, and antisense nucleotides.

 

Ian enjoys working for a range of clients, from multinational pharmaceutical firms to a number of university spin-outs and start-ups, many of which he has helped for years as their businesses develop. As such, Ian has extensive experience drafting and filing patent applications to build up portfolios and then coordinating the prosecution of applications around the world. Ian also has a substantial opposition practice and represents his clients defending and opposing key patents, in particular at the European Patent Office.

 

Aletta Kraneveld

Professor of Pharmacology
Utrecht University

Aletta Kraneveld studied Pharmacy at the schools of Pharmacy at University of Amsterdam and Utrecht University. As a junior researcher she worked at the department of Gastrointestinal Pharmacology of Glaxo Group Research in the UK (1990-1991). She obtained her PhD at the department of Pharmacology, Faculty of Pharmacy, Utrecht University (1994) after which she did an internship at the department of Pathology, Harvard Medical School Boston MA, USA (PI Steve Galli). As a post doc she continued her research as immune-pharmacologist in Utrecht.

Aletta Kraneveld

Professor of Pharmacology
Utrecht University

Aletta Kraneveld studied Pharmacy at the schools of Pharmacy at University of Amsterdam and Utrecht University. As a junior researcher she worked at the department of Gastrointestinal Pharmacology of Glaxo Group Research in the UK (1990-1991). She obtained her PhD at the department of Pharmacology, Faculty of Pharmacy, Utrecht University (1994) after which she did an internship at the department of Pathology, Harvard Medical School Boston MA, USA (PI Steve Galli). As a post doc she continued her research as immune-pharmacologist in Utrecht. In 1998 Aletta was appointed as assistant professor and in 2002 as associate professor at the division of Pharmacology of the department of Pharmaceutical Sciences of the Utrecht University. She has published 80 papers (H-index: 30). Besides science, she is an active member of several boards of (inter)national scientific organizations (Dutch Society of Pharmacology, EPHAR, IUPHAR, Netherlands Federation of Innovative Drug research).. 

 

Alexis Mosca

Physician Pediatrics
Robert-Debré Hospital

Alexis Mosca

Physician Pediatrics
Robert-Debré Hospital
 

John Kokai-Kun

VP, Non-Clinical Affairs
Synthetic Biologics

John Kokai-Kun

VP, Non-Clinical Affairs
Synthetic Biologics
 

Katri Korpela

Professor
Department of Bacteriology and Immunology, University of Helsinki

Katri Korpela

Professor
Department of Bacteriology and Immunology, University of Helsinki
 

Dr Maria Kyrgiou

Clinical Senior Lecturer
Imperial College London

Dr Maria Kyrgiou is a Clinical Senior Lecturer at Imperial College London and Consultant Gynaecologist and Gynaecologic Oncologist at the West London Gynaecological Cancer Centre, Imperial Healthcare NHS Trust.

Dr Maria Kyrgiou

Clinical Senior Lecturer
Imperial College London

Dr Maria Kyrgiou is a Clinical Senior Lecturer at Imperial College London and Consultant Gynaecologist and Gynaecologic Oncologist at the West London Gynaecological Cancer Centre, Imperial Healthcare NHS Trust.

The primary focus of her research is traslational research in gynaecological cancers, in particular cervical and endometrial cancer. She has led research into the impact of treatment for cervical pre-invasive and early invasive cervical disease on reproductive outcomes and the clinical use of HPV biomarkers in personalising the management of women with abnormal findings at screening. She has an interest in the role of obesity and metabolic disorders in endometrial tumorigenesis.

 

Tine Rask Licht

Professor, Head of Research Group
National Food Institute, Technical University of Denmark

Tine Rask Licht heads the The National Food Institute research group on Intestinal Microbial Ecology. 

The focus of our research is on effects of diet on composition, activity and genetic exchange in the gut microbiota, as well as on effects of the gut environment on resistance to pathogenic infections. Additionally, we adress the impact of gut microbes on maturation and maintenance of the host immune system. We look at effects of whole food items as well as of prebiotic carbohydrates and probiotic bacteria.

Tine Rask Licht

Professor, Head of Research Group
National Food Institute, Technical University of Denmark

Tine Rask Licht heads the The National Food Institute research group on Intestinal Microbial Ecology. 

The focus of our research is on effects of diet on composition, activity and genetic exchange in the gut microbiota, as well as on effects of the gut environment on resistance to pathogenic infections. Additionally, we adress the impact of gut microbes on maturation and maintenance of the host immune system. We look at effects of whole food items as well as of prebiotic carbohydrates and probiotic bacteria.

 

Tim Luker

Director External Innovation, Global External R&D
Eli Lilly and Company

Tim Luker

Director External Innovation, Global External R&D
Eli Lilly and Company
 

Thomas Clavel

Senior scientist
Technische Universität München

The main focus of our research is the study of intestinal microbiomes (the communities of microorganisms, their genomes, and surrounding environmental factors in the gut). Because intestinal microorganisms have a major impact on the physiology of their host, it is important to investigate and understand their diversity and functions. We focus primarily on the human, pig, and mouse gut microbiomes because of their relevance for health-related issues.

Thomas Clavel

Senior scientist
Technische Universität München

The main focus of our research is the study of intestinal microbiomes (the communities of microorganisms, their genomes, and surrounding environmental factors in the gut). Because intestinal microorganisms have a major impact on the physiology of their host, it is important to investigate and understand their diversity and functions. We focus primarily on the human, pig, and mouse gut microbiomes because of their relevance for health-related issues. In particular, we are interested in describing the taxonomic diversity and evolution of gut bacteria thanks to the use of culture-based and sequencing approaches. 

 

Sophie Leclercq

Post-doctoral researcher
Université catholique de Louvain

Sophie Leclercq

Post-doctoral researcher
Université catholique de Louvain
 

Sara Romano-Bertrand

Assistant Professor
Université Montpellier

I work on opportunistic bacterial pathogens from endogenous (from human-associated microbiota) or exogenous (environment) origins, involved in healthcare-associated infections (HAI). Conversely to true bacterial pathogens that accord with the Koch’s postulate, the study of opportunistic infections including HAI, require us to consider both opportunistic pathogens responsible for the infection, its natural reservoir an the microbial-associated communities.

Sara Romano-Bertrand

Assistant Professor
Université Montpellier

I work on opportunistic bacterial pathogens from endogenous (from human-associated microbiota) or exogenous (environment) origins, involved in healthcare-associated infections (HAI). Conversely to true bacterial pathogens that accord with the Koch’s postulate, the study of opportunistic infections including HAI, require us to consider both opportunistic pathogens responsible for the infection, its natural reservoir an the microbial-associated communities. This intricate consideration of the opportunistic infection is based on the innovative concept of the “pathobiome”, which integrates the complex interactions between microorganisms and considers opportunistic bacteria within its microbial community, within its hosts and its environment, in the pathologic context, in order to explain the occurrence of the infection. 

 

Rose Szabady

Senior Staff Scientist
Vedanta Biosciences, Inc.

Rose Szabady

Senior Staff Scientist
Vedanta Biosciences, Inc.
 

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Dr. Mike Romanos, Ph.D. serves as the Chief Executive Officer at Microbiotica Ltd. He served as the Chief Executive and Executive Director of Crescendo Biologics Limited. Dr. Romanos is employed at Midven Limited. He is Venture Partner of Rainbow Seed Fund. He has more than 20 years' biotech and pharmaceutical industry experience, and within the last 10 years has held international executive positions in GlaxoSmithKline R&D before moving to take leadership of Crescendo Biologics.

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Dr. Mike Romanos, Ph.D. serves as the Chief Executive Officer at Microbiotica Ltd. He served as the Chief Executive and Executive Director of Crescendo Biologics Limited. Dr. Romanos is employed at Midven Limited. He is Venture Partner of Rainbow Seed Fund. He has more than 20 years' biotech and pharmaceutical industry experience, and within the last 10 years has held international executive positions in GlaxoSmithKline R&D before moving to take leadership of Crescendo Biologics. His industry and science experience covers most areas of drug discovery science and technology, and several therapeutic areas. During his career he has made significant contributions to GSK's drug development pipeline, and broadly to drug discovery strategy and technology.

 

Martha Clokie

Professor of Microbiology
University of Leicester

My research focuses on identifying, characterising and developing bacteriophages (viruses) that target and kill bacterial pathogens of medical relevance with the view to identifying novel antimicrobials. I have published over 60 papers in both on the fundamental and applied aspects of bacteriophages. Clearly this work has been impacted by our increasing concerns regarding antibiotic resistance because bacteriophages as natural enemies of bacteria can either be exploited as natural viruses, or they may encode novel products with antimicrobial properties.

Martha Clokie

Professor of Microbiology
University of Leicester

My research focuses on identifying, characterising and developing bacteriophages (viruses) that target and kill bacterial pathogens of medical relevance with the view to identifying novel antimicrobials. I have published over 60 papers in both on the fundamental and applied aspects of bacteriophages. Clearly this work has been impacted by our increasing concerns regarding antibiotic resistance because bacteriophages as natural enemies of bacteria can either be exploited as natural viruses, or they may encode novel products with antimicrobial properties.

My work is rooted in an ecological framework which I use both for virus discovery and the manipulation of microbiota associated with disease.  My major focus has been on Clostridium difficile where I have isolated and characterised a large bacteriophage collection, and where I have developed in vitro, ex situ and in vivo models to assess the mechanistic interactions of phages with their bacterial hosts and to assess their therapeutic potential.  I am now developing these phages as therapeutics. I also have active projects to study bacteriophages that target many other bacterial species including Pseudomonas aeruginosa, Streptococcus spp., Borrelia, Haemophilus and Salmonella

In terms of my formal education and training, I obtained a BSc in Biology from Dundee University in 1996 an MSc in Biodiversity from Edinburgh University in 1997, and a PhD from Leicester in Molecular Ecology in 2001. I then did 6 years of Post-Doctoral research at the University of Warwick and in Scripps, La Jolla, San Diego.  In 2007 I was appointed as a lecturer at Leicester, in 2011 a Reader and in 2016 I was promoted to Professor of Microbiology.

 

Richard Dennett

Director, CMC & Quality
Voisin Consulting Life Sciences

Richard Dennett

Director, CMC & Quality
Voisin Consulting Life Sciences
 

Tim Adetona, M.Sc., D.PH

Director, Drugs & Nutraceuticals
Voisin Consulting Life Sciences

Tim has a broad regulatory expertise of close to 20 years’ experience (5 as Consultant) in addressing and obtaining regulatory authorization for various life-science products including drugs, biologics and innovative nutritional products in Europe, as well as statutory regulatory requirements in global markets including the USA and emerging markets.

Tim Adetona, M.Sc., D.PH

Director, Drugs & Nutraceuticals
Voisin Consulting Life Sciences

Tim has a broad regulatory expertise of close to 20 years’ experience (5 as Consultant) in addressing and obtaining regulatory authorization for various life-science products including drugs, biologics and innovative nutritional products in Europe, as well as statutory regulatory requirements in global markets including the USA and emerging markets.

Tim has acquired significant knowledge of Swiss regulations and Swissmedic procedures and has successfully managed a number of MAA submissions for drugs and biologics. Tim has substantial experience in all steps of product development from preclinical to life-cycle management, including those involving specialized conditions as orphan drug designations, accelerated or fast-track assessment procedures and compassionate use programs.

Tim also has responsibility for the management of projects involving the design and implementation of global regulatory strategies for the development, evaluation and marketing of nutritional and innovative food-drug borderline products. Tim is equally well versed in regulatory engagements involved with the development of Personal, Health and Beauty Care products (cosmetics, deodorants and antiperspirants), as well as Medical Devices and OTC medicines.

Prior to joining VCLS, Tim was Regulatory Affairs Director, Consumer Health Care International (CHCI) for Vifor Pharma, where he provided directional leadership for the implementation of all aspects of Regulatory Affairs related to Consumer Health Care products in global markets and successfully expanded the experience he had gained as Senior Regulatory Affairs Manager for Procter & Gamble.

2017 Sponsors

Media Partners

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

The Agenda

What You Can Expect From This Year's Congress:

  • 250+ Academic and Industry Leaders Onsite
  • 40+ Thought Leaders on the Speaker Faculty
  • 50:50 Ratio of Academics-Industry
  • 19 One-on-One Private Meetings per Attendee

European Microbiome Congress agenda

Download Full Agenda

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Venue

Millennium Mayfair Hotel, Grosvenor Square, London W1K 2HP

Kisaco Research is pleased to offer attendees of The European Microbiome Congress a discounted £225 (excl vat) rate including breakfast at the Millennium Mayfair Hotel during the duration of the event.

TO BOOK ACCOMMODATION
Telephone: 0044 (0) 207 629 9400 quote KISA261117 when booking.

Email: [email protected] quote KISA261117 when booking.

Cut off date for rooms is 29 October 2017.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Academics, Clinicians, Students & Post-Doctoral Researchers
£995 +VAT
2-Day Main Conference
One-to-One Meeting Scheduler
Post-Show Access to Presentations
Welcome Networking Reception
Poster Sessions
Complimentary Articles and Content
Daily Lunches & Refreshments
Pharmaceutical and Biotech
£1,995 + VAT
2-Day Main Conference
One-to-One Meeting Scheduler
Post-Show Access to Presentations
Welcome Networking Reception
Poster Sessions
Complimentary Articles and Content
Daily Lunches & Refreshments
Service Providers, Vendors
£2,295 + VAT
2-Day Main Conference
One-to-One Meeting Scheduler
Post-Show Access to Presentations
Welcome Networking Reception
Poster Sessions
Complimentary Articles and Content
Daily Lunches & Refreshments
Poster Session
£50
FREE for attendees (£50 for Non-Attendees)
Poster Session
Preparing registration...

Poster Presentation Submission

If you are looking to highlight your recent work to the wider microbiome community, the dedicated poster session is a great way to get your research noticed and further involve yourself with the congress. In order to present a poster, you need to be registered as a delegate. Poster space is assigned on a first come, first served basis. Your presentation will be displayed in a dedicated poster area, while presentation sessions will take place both in the breaks and alongside sessions at prescheduled times.

PLEASE CLICK HERE TO DOWNLOAD THE SUBMISSION FORM

Rising Star Travel Grant

£200 Travel Grants are available for FIVE young researchers (defined as having completed their PhD within the last 5 years). To be considered for one of the Rising Star Travel Grants, you must submit an abstract before 31st October 2017.

PLEASE CLICK HERE TO DOWNLOAD THE SUBMISSION FORM

Commercialisation Surgery

Attendees are invited to pose questions and seek advice from a panel of industry leaders who have been through the commercialisation process.

SUBMIT YOUR QUESTIONS HERE

Innovation Stage

Academics and early stage start-ups are invited to present innovations that they are looking to commercialise. Whether you are looking for investment or just want an expert’s opinion on the next steps in your commercialisation journey, this platform will be valuable for you. This platform allows FOUR presenters to share as much or as little information around their innovation as they feel comfortable, and receive tips and advice from a panel of expert investors, consultants, pharmaceutical companies, lawyers and successful start-ups, as well as input from the audience.
APPLY HERE

Book a Team to Save More!

Industry Rates Only: Team discounts cannot be combined with any other discount or offer

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for the the Microbiome Conference:

  • Please note that a £49 processing fee will apply to any invoices requested.
  • * You must email us a signed letter from the Hospital / Clinic Supervisor or University / Laboratory with confirmation of your status upon payment
  • All Prices are in GBP
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • All discount offers cannot be combined with any other offer.
  • Please view our Cancellation Policy.
  • All Price exclude GB VAT of 20% – GB201759917

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Resources

Download Resource

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.